Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

166.80 -18.70 (-10.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) ↗
 
Via Benzinga
News headline image
Despite its growth, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) remains within the realm of affordability. ↗
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
NEUROCRINE BIOSCIENCES INC has a stellar value proposition. NASDAQ:NBIX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
News headline image
NASDAQ:NBIX is showing decent growth, but is still valued reasonably. ↗
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
News headline image
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts ↗
 
Via Benzinga
News headline image
Why Neurocrine Biosciences Stock Sank Today ↗
Via The Motley Fool
News headline image
Why the quality investor may take a look at NASDAQ:NBIX. ↗
A fundamental analysis of (NASDAQ:NBIX): Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
News headline image
Earnings Summary: Neurocrine Biosciences Q4 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 6, 2025 ↗
 
Via Benzinga
News headline image
Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio? ↗
Skyworks Solutions, Estee Lauder, Venture Global, Neurocrine Biosciences, Moderna, Illumina, IDEX Corporation, PTC Inc, PayPal Holdings, Skechers U.S.A. and Avantor were worst performers, fell up to... 
Via Benzinga
News headline image
Why Is Neurocrine Biosciences Stock Trading Lower On Friday? ↗
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges. 
Via Benzinga
News headline image
Neurocrine Biosciences Reports Mixed Q4 ↗
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug ↗
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza. 
Via Investor's Business Daily
News headline image
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
NASDAQ:NBIX: good value for what you're paying. ↗
Investors should take notice ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. ↗
Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
News headline image
NASDAQ:NBIX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
NEUROCRINE BIOSCIENCES INC may be an undervalued stock option. NASDAQ:NBIX retains a strong financial foundation and an attractive price tag. 
Via Chartmill
News headline image
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights ↗
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal. 
Via Benzinga
News headline image
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
News headline image
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
News headline image
Neurocrine Biosciences Stock Sees RS Rating Upgrade ↗
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
Via Investor's Business Daily
News headline image
What Analysts Are Saying About Neurocrine Biosciences Stock ↗
 
Via Benzinga
News headline image
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable. ↗
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
News headline image
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential ↗
Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation. 
Via Benzinga
News headline image
Neurocrine Wins FDA Approval For Genetic Disorder Drug ↗
The company can launch within a week, says Chief Executive Kyle Gano. 
Via Investor's Business Daily
News headline image
Screening For Black Friday Bargains In The Stock Market ↗
 
Via Benzinga
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.